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ABSTRACT 
Dissolution and diffusion through the gastrointestinal membrane are the mechanisms by which drugs get absorbed on oral administration. The 
major challenge in the case of most of the drugs is poor water solubility. Hence the main aim of the present study is to develop Nanocomposites 
by microwave-assisted technique to enhance solubility and dissolution of poorly water-soluble drug Fenofibrate. Synthetic polymers such as 
PVP K30 was selected for Nanocomposites preparation based on it's wetting and surface active agent property. Nanocomposites w ere prepared 
by Microwave-assisted technique and characterized by Fourier transform infrared spectroscopy, differential scanning calorimetry, X-ray 
diffraction studies, scanning electron microscopy and transmission electron microscopy. The solubility and dissolution enhanc ing the 
performance of Nanocomposites were assessed by In-vitro solubility and dissolution studies. It was demonstrated that the dissolution of 
Fenofibrate enhanced with an increase in polymer concentration. The optimized ratio of drug and polymer for the entire composite was found 
to be 1:9 Nanocomposites with PVP K30. The Microwave-assisted technique employed in this study as a green and cost-effective method for 
Nanocomposites formation. Enhancement in the solubility might be because of the generation of drug dispersion at nanoscal e levels. So the 
development of Nanocomposites is a promising approach to increase solubility and dissolution of poorly water-soluble drugs. 
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INTRODUCTION: 
The solubility of the drug is the most difficult aspect of the 
formulation and development.1 Drug effectiveness can be 
severely limited by poor aqueous solubility and most of the 
drug also show side effect due to their poor solubility. 
Increasing drug solubility increases efficiency and minimizes 
the side effects of certain drugs.2,3,4 Drugs having poor water 
solubility are associated with slow drug absorption and 
finally inadequate or diverse bioavailability. Today near 
about 40 % of newly synthesized drugs have the problem of 
poorly water solubility.5 The poor aqueous solubility of the 
drug in the gastrointestinal fluid often causes inadequate 
bioavailability. These drugs require a high dose to achieve 
therapeutic plasma concentration. At the site of action, 
aqueous form preferred for oral administration.6,7  
According to the Biopharmaceutical Classification System 
(BCS), most of the drugs displaying insolubility belong to 
BCS class II. This class encompasses drugs having low water 
solubility with high membrane permeability. Hence 
dissolution will be the rate-limiting step in drug absorption 
from the oral solid dosage forms of this class.8 This problem 
can be ameliorated by using various solubility enhancement 
techniques, one of the most formidable aspects of drug 
development. A reduction in particle size leads to an 
increase in surface area and therefore the dissolution rate 
increases. Nanonisation has been introduced to achieve a 
particle size between 100 nm and 1000 nm. The formulation 
of nanosized particles could be applied to BCS class II drugs 
to improve their solubility and dissolution and hence 
bioavailability.9,10 Nanonisation is advantageous not only 
due to the increase in drug dissolution but also the increase 
in saturation solubility. There are abundant techniques to 
reduce the drug powder particle size to the nanoscale, like 
nano crystallization, nanoprecipitation, jet milling, pearl 
milling, high-pressure, and supercritical fluid technology.11,12 
A decrease in particle size results in an increase in Gibbs free 
energy by increasing the extra ‘subdivision potential’ term, 
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which is mainly related to the increase in surface energy.13,14 
This extra Gibbs energy related to particle size reduction is 
compensated for by the use of surface-stabilizing materials 
and an external energy source.15 Numerous stabilizing 
techniques have been used for stabilizing nanoparticles, 
including an addition of one or more stabilizing 
materials,16,17 ionic or steric stabilization of hydrophobic 
drugs18 and polymeric stabilizers in wet comminution. From 
the analysis of state-of-the-art techniques, it emerges that 
the latest and most effective approaches to the solubilization 
of water-insoluble drugs are based on generating a drug 
dispersion (at molecular and/or nanoscale level) in a 
stabilizing media, preferably in solid-state form.19 In existing 
research, authors have engendered such a system by use of 
microwave irradiation, which is a green and effective 
instrument for generating molecular dispersions.  
Microwave irradiation is electromagnetic irradiation located 
between the infrared and radio frequencies in the range of 
0.3–300 GHz, which corresponds to wavelengths of 1 cm to 1 
m. Microwave techniques were introduced into the 
pharmaceutical field for various applications such as the 
formation of gel beads, agglomerates, nanomatrix, 
microspheres, film coats, tablets, and solid dispersions.20 
Microwaves can be directly converted into heat inside the 
material. Therefore, it is possible to achieve rapid and 
uniform heating even in materials exhibiting low heat 
conductivity, such as polymers, because the transfer of 
energy does not rely on heat diffusion. This is very 
important in the preparation of drug formulations because 
many excipients are polymers. This mechanism is employed 
widely for making polymeric cross-linkages as well as drug-
polymer interaction, drying and structural modification of 
drug crystals via its effects of heating.21 The first unique 
approach towards the formation of nanocomposites was 
done by Kerc et al. who used silicon dioxide as the substrate 
for adsorption of the drug; however, recrystallization of the 
drug was found to be a major problem due to the high 
mobility of drug molecules on inorganic surfaces.22 Bergese 
et al. replaced the inorganic surface with inert three-
dimensional matrixes (cyclodextrin, crospovidone) that 
possess suitable microstructural properties for preventing 
recrystallization of the drug.19 The use of natural carriers in 
solubility and dissolution enhancement is an innovative 
concept. In the current investigation, we have disseminated 
synthetic polymers as a composite material for 
incorporating fenofibrate in the nanocrystalline form with 
the help of microwave-induced diffusion (MIND), which is a 
green and effective way of generating nanocomposites. The 
polymers selected were polyvinylpyrrolidone and 
croscarmellose sodium. The polymers were selected based 
on their good surfactant and wetting properties, which 
additionally aid the enhancement of solubility and 
dissolution and, ultimately, bioavailability.23 
Fenofibrate is a drug of the fibrate class. It is mainly used to 
decrease cholesterol levels in people at risk of 
cardiovascular disease. Like other fibrates, it reduces low-
density lipoprotein (LDL) and very-low-density lipoprotein 
(VLDL) levels, as well as increasing high-density lipoprotein 
(HDL) levels and reducing triglyceride levels4. Fenofibric 
acid is the metabolite of fenofibrate, which produces a 
reduction in LDL, total triglycerides and VLDL in patients. 
Treatment with fenofibrate results in increased HDL and 
apoproteins apo AI and apo AII6. Fenofibrate is used for 
primary hypercholesterolemia or mixed dyslipidemia. 
Fenofibrate reduces the risk of cardiovascular disease and 
diabetic retinopathy in patients with diabetes mellitus and 
indicated for reducing the progression of diabetic 
retinopathy in patients with type 2 diabetes. It helps 
decrease amputations of the lower legs 7.24 
MATERIAL AND METHODS: 
Fenofibrate was purchased from Cipla Pharmaceutical 
limited, Mumbai (India). Polyvinylpyrrolidone and 
Carboxymethyl cellulose Sodium were kindly supplied by 
Research-Lab Fine Chem. Industry, Mumbai. Microcrystalline 
cellulose, Croscarmellose sodium, Calcium hydrogen 
phosphate, Maltose, and Magnesium stearate was obtained 
as a gift sample from Research-Lab Fine Chem. Industry, 
Mumbai. The materials were used as received without any 
further purification. 
Characterisation of Gums:23 
Swelling characteristics 
Accurately weighed 10 g of Polyvinylpyrrolidone and 
Carboxymethyl cellulose Sodium were placed in a 100-ml 
measuring cylinder. The initial volume of polymers was 
noted, and the cylinder was filled with distilled water up to 
100 ml. The cylinder was kept aside for 24 h, and the volume 
of swelled polymers was noted. Swelling index (SI) was 
expressed as a percentage and calculated according to the 
following equation: 
            
     
  
     
Where, X0 is the initial height of the powder in the graduated 
cylinder and Xt denotes the height occupied by swollen 
polymers after 24 h. 
Viscosity determination 
One gram each of Polyvinylpyrrolidone and Carboxymethyl 
cellulose sodium respectively was dispersed in 100 ml 
distilled water (1% w/v). The viscosity of the resultant 
dispersions was measured by a viscometer (Brookfield DV-E, 
Brookfield Engineering Laboratories, Inc., Middleboro, MA, 
USA.) using spindle 3 at 100 rpm. 
Foaming index 
The foaming index of the polymers was measured to 
establish their surfactant properties. One gram of polymer 
was dispersed in 100 ml distilled water and vigorously 
shaken for 2 min. 
The foaming index was calculated by the following equation: 
                    
Where, Vf is the volume of 1% w/v solution of polymer after 
shaking and Vi is the volume of 1% w/v solution of polymer 
before shaking.  
Preparation of Nanoocmposites:23  
Physical Mixtures 
A physical mixture of the drug (FNO) with polymers (PVP, 
CMCNa) was prepared respectively by the simple blending of 
drug with the polymer in 1:3, 1:6, 1:9 ratios (drug: polymer) 
for 10 min. The physical mixture of drug with polymer was 
denoted with symbol FNO:PVP and FNO:CMCNa (Where FNO 
indicates Fenofibrate; PVP indicates Polyvinylpyrrolidone; 
CMCNa indicates Carboxymethyl cellulose sodium).    
Preparation of Nanocomposites 
For each sample, a physical mixture of Fenofibrate and the 
individual carrier was made by homogenous mixing. The 
weight to weight (w/w) ratios of the drug was taken in 3 
ratios keeping the amount of mixture constant. To this 
mixture, 4 ml of water was added for each gram of the drug 
carrier mixture to make a homogenous slurry. A fixed 
amount of slurry was placed in a glass beaker with a Teflon 
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stirrer (transparent to microwave) and treated with 
microwave irradiation for different times at power of 
400W(Electrolux MC009SS). The temperature of the mixture 
at the end of treatment was recorded. The sample was then 
ground in the mortar and pestle and sieved to achieve a 
particle size of 80-250µm. The Nanocomposites of drug with 
the carrier respectively. The process variable is shown in the 
Table 1. 
 
Table 1: Process variable for preparation of Fenofibrate Nanocomposites 
Sample Ratio (w/w) Time (min)  Final temp. range (0C) 
FNOPVPM 1:3, 1:6, 1:9 24 180-200 
FNONaCMCM 1:3, 1:6 ,1:9 24 220-240 
 
Evaluation of Nanocomposites:23 
Solubility studies: 
The solubility of FNO and FNOPVP was determined in water. 
The solubility of drug and nanocomposites was determined 
by taking an excessive amount of drug (40 mg), 
nanocomposites (equivalent to 40 mg drug) and added them 
in 10 ml of above solvent, in vials. The samples were kept at 
equilibrium for a period of 72 hrs. in an incubator at 
37±0.500C with occasional shaking. The supernatant 
collected from vials was filtered through Whatman filter 
paper and analyzed by UV- visible spectrophotometer 
(Shimadzu 1800) at the respective wavelength. 
Drug Content Analysis: 
Drug content analysis was performed to study the amount of 
drug incorporated in the nanocomposites. FNO 
nanocomposites equivalent to 40 mg of pure FNO was 
weighed and dissolved in 10 ml methanol, further 1 ml was 
withdrawn from the above and diluted 10 ml with methanol 
again 1 ml from the above solution was withdrawn and 
diluted to 10 ml with methanol. FNO content in the 
methanolic extract was analyzed spectroscopically at 
respective wavelengths, against methanol as blank. 
Where,  
               
  
   
     
Wa = Actual drug content, 
Wt = Theoretical drug content 
Dissolution study of FNO Nanocomposites: 
The dissolution test of an optimized ratio was carried out 
following the USP XXIV Apparatus 2 (paddle) method. The 
dissolution media, paddle speed, bath temperature, and UV 
analysis was done as per Table 2.  5 ml Of Aliquots were 
collected periodically and replaced with fresh dissolution 
medium. Aliquots, after Filtration through Whatman filter 
paper (No.41), were analyzed spectroscopically. Each 
sample was analyzed in triplicate. 
 
Table 2: Dissolution Studies of FNO Nanocomposites 
Drug Dissolution 
Medium (900 
ml) 
Paddle 
speed 
(RPM) 
Total 
Time (Hr) 
Sample 
interval (mins) 
Bath Temperature 
(0C) 
UV analysis 
(wavelenmg-ht nm) 
FNO Phosphate buffer 
pH 6.8 
50 2 5,10,15,20,25,30 37 ± 0.5 286 
 
Characterization of Nanocomposites:23 
Fourier-transform infrared spectroscopy 
Fourier-transform infrared (FTIR) spectra of pure drug FNO 
and Nanocomposite (FNO: PVP) were taken to access 
interaction, if any, between drug and gum in mixtures. 
Nanocomposites were mixed with potassium bromide (KBr) 
of IR grade in the ratio 1:100 and compressed using 
motorized pellet press at 15 tone pressures. The pellets were 
then scanned using an FTIR spectrophotometer (Bruker). 
The FTIR spectra of mixtures and pure drug to assess any 
change in the principle peaks of spectra of pure drug. 
Differential scanning calorimetry 
Differential Scanning calorimetry (DSC) studies of pure drug 
FNO, pure polymer (PVP) and Nanocomposite (FNO: PVP) 
was performed to assess what changes had occurred when 
nanocomposite was formed by what phenomenon these 
enhanced drug solubility. The sample was weighed in 40µl 
aluminum pans was approximately (2-4 mg) and were 
sealed. An empty aluminum pan was used as a reference. DSC 
thermograms were obtained at a heating rate of 100C/min 
from 0 to 3000C in a nitrogen atmosphere.  
X-ray Diffraction Studies 
XRD studies of the drug (FNO) and Nanocomposite was 
carried out to assess the changes in the crystallinity made 
when the drug was mixed with the polymer. 
Scanning Electron Microscopy 
Nanocomposite that showed the best results in the solubility 
and dissolution studies were subjected to Scanning electron 
microscopy (SEM) studies to confirm the changes made 
during the formation of the nanocomposite. 
Transmission Electron Microscopy  
The optimized ratio of nanocomposite showing best results 
in the solubility and dissolution studies was subjected to 
Transmission electron microscopy (TEM) studies to confirm 
the formation of nanocrystals embedded in composites. 
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Preparation of Immediate-Release Tablets 
The ratios of Nanocomposites that showed the best results in 
solubility and dissolution studies were selected for 
formulating the immediate-release tablets. Superdisintegrant 
carboxymethyl cellulose sodium was used for formulating 
immediate-release tablets. The composition of tablets was as 
shown in Table 2. All the components of the tablets were 
sieved through a #60 sieve, weighed, mixed and compressed 
by direct compression into tablets using a 12-mm punch for 
GPZGLTM tablets on rotary tablet Minipress (Rimek 
Minipress Karnavati engineering, Ahmedabad). 
 
Table 3.  Content of Immediate Release Tablets of Fenofibrate Nanocomposites 
Ingredients Quantity in Batch 
F1 F2 F3 F4 F5 
Nanocomposites(≈40mgFNO) 360 360 360 360 360 
Croscarmellose Na 05 10 15 20 25 
Microcrystalline cellulose 40 45 50 55 60 
Calcium hydrogen phosphate 82 77 72 67 62 
Mannitol 3 3 3 3 3 
Magnesium stearate 5 5 5 5 5 
Talc 5 5 5 5 5 
 
Evaluation of Immediate-Release Tablet:23 
Pre-compression evaluation 
The pre-compression evaluation included measurement of 
the angle of repose, Carr’s index (compressibility) and 
Hausner’s ratio of optimized Nanocomposites and various 
formulation mixtures, following the procedures given in USP 
30 (2007). 
Post-compression evaluation 
Post-compression evaluation included measurement of 
weight variation, hardness, friability, drug content and 
disintegration time of prepared formulations, following the 
procedures given in USP 30 (2007). 
Assay of the total drug content 
Drug content analysis was performed to study the amount of 
drug incorporated in tablets. fenofibrate from powdered 
tablets was extracted by dissolving the tablets in 25 ml 
methanol. The resulting solution was filtered by using a 0.2- 
micron membrane filter. Fenofibrate content in the 
methanolic extract was analyzed spectrophotometrically at 
286 nm against the methanol as blank 
In-vitro Drug Release Study  
An In-vitro drug release studies of the prepared nine 
formulations of immediate-release tablets were conducted 
for 40 min using eight stations USP Type 2 Apparatus 
(paddle type). The agitation speed was 500 rpm. FNO tablet 
was added to 900 ml phosphate buffer pH 6.8 at 37 ± 0.50C. 
5 ml aliquots were withdrawn at time intervals of 5, 10, 15, 
20, 25, 30 min. and filtered through Whatmans No. 41 filter 
paper. An equal volume of fresh dissolution medium was 
replaced to maintain the volume of the dissolution medium. 
The filtered samples were analyzed spectrophotometrically 
at 286 nm. The cumulative percentage of the labeled amount 
of drug released was calculated. 
Stability Studies:23 
The optimized formulation was wrapped in aluminum foil 
and subjected to 40 ± 20C temperature and 75 ± 5% RH in 
the stability chamber for 3 months. The formulation was 
analyzed for organoleptic characteristics, Thickness, 
Hardness, Drug content, Disintegration time, Weight 
variation, Dissolution. In any rational design and evaluation 
of dosage forms for drugs, the stability of the active 
component is the major criteria in determining their 
acceptance or rejection. Stability studies were carried out as 
per ICH Q1A guidelines. During the stability studies, the 
product is exposed to normal conditions of temperature and 
humidity. The optimized Fenofibrate formulations were 
subjected to stability studies. Tablets were wrapped in 
aluminum foils. The optimized formulations were subjected 
to stability for 3 months. The sample was withdrawn at the 
end of the 3 months.  
RESULT AND DISCUSSION 
Physical Characterization of the polymer. 
Results of swelling, viscosity, and foaming of polymers are 
shown in Table 4. From results, it can be concluded that the 
swelling characteristics and viscosity of PVP are low than 
NaCMC. It indicates that because of low swelling and low 
solution viscosity they are less prone to the formation of the 
matrix which will assist rapid liberation of the nanocrystals 
from the Nanocomposites. Additionally, the foaming index of 
these polymers indicated that PVP has the best foaming 
ability. Hence, PVP enhances the solubility more efficiently as 
compared to NaCMC. 
 
Table 4: Description of additives used in formulation 
Material % Swelling Viscosity (cps) Foaming Index 
Carboxymethyl cellulose 
sodium(NaCMC) 
65.62±1.21 3.820±0.36 15±0.84 
Polyvinly pyrollidone 
(PVP) 
63.82±1.68 3.560±0.29 17±0.78 
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Evaluation of Nanocomposites: 
Dissolution Studies 
Dissolution studies were performed to analyze the solubility 
enhancing properties of polymers. Dissolution studies gave 
the basis for the selection of best ratio that is to be 
forwarded for formulation. Nanocomposites of drug with the 
polymer in the various ratio were analyzed for solubility 
determination. The results of the same are shown in Table 5. 
These studies reveal that PVP having very good solubility 
enhancing property as they have good surfactant properties 
and reduction of crystal size of the drug to nanoscale in the 
form of Nanocomposites enhances the solubility. Solubility 
studied of Nanocomposites indicated that as the ratio of 
drug to polymer increases solubility also increases. It was 
also found that after a certain ratio i.e. 1:9 solubility remains 
constant hence 1:9 ratio was optimized. 
 
Table 5: Dissolution study of Nanocomposites 
Time(min) Fenofibrate Nanocomposites (FNO:PVP) 
 
1:3 1:6 
 
1:9 
5 18.26±0.028 15.62±0.014 21.82±0.015 24.32±0.026 
10 33.85±0.015 20.85±0.062 32.6±0.062 45.15±0.052 
15 39.85±0.02 29.79±0.10 46.78±0.045 67.64±0.02 
20 44.65±0.032 36.35±0.023 54.74±0.052 79.82±0.025 
25 54.67±0.025 45.25±0.051 64.02±0.036 86.68±0.05 
30 61.82±0.015 51.32±0.35 72.65±0.28 97.32±0.028 
 
Drug Content Analysis: 
Drug content analysis was performed to study the % amount 
of drug incorporated in the Tablet. After drug content 
analysis studies it was found that almost 96 to 101% of the 
drug was incorporated in the Tablet indicates uniform 
dispersion of drug. 
Characterisation of Nanocomposites 
Fourier-transform infrared spectroscopy studies 
Infrared spectra of drug and polymers showed matching 
peaks with the drug spectra. The data obtained from the IR 
spectra showed no evidence of the interaction between the 
drug and the polymer studies. All the major characteristic 
peaks of the drug were present in the drug-polymer 
combinations subsequent spectra. Overlay spectrum of 
Fenofibrate with individual polymer is shown in Fig 1 & 2 
And interpretation of FTIR spectrum of Fenofibrate and 
drug-polymer physical mixtures are shown in Table 6. 
  
 
Fig.1 FTIR of Fenofibrate                                          Fig.2 FTIR of Nanocomposites 
 
Table 6: The interpretation of Infra-red spectra of Fenofibrate and Polymers. 
Sr. 
No. 
Functional Group Wavenumbers (cm-1) 
FNO Physical mixture Standard values (cm-1) 
1 C=O stretch 1729.76 1726.65 1725-1705 
2 C-Cl 764.41 764.36 785-540 
3 C-O stretch ester 1302.43 
1248.14 
1182.33 
1173.95 
1302.32 
1287.35 
1249.33 
1026.62 
1320-1000 
4 Para-substitution 843.94 
818.94 
925.30 800-850 
5 C=C sretch 2933.72 
2984.43 
2983.94 
2925.70 
3000-2850 
6 C-H sretch 1650.99 1651.41 1680-1600 
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Differential Scanning Calorimetry 
DSC Thermogram of the pure drug (FNO) and 
Nanocomposites is shown in Figures 3 and 4. The crystalline 
nature of Fenofibrate can be easily recognized by the 
presence of a sharp endothermic peak at around 78.020C. 
The same endothermic peak with decreased intensity was 
observed in the DSC profile of FNOPVP (1:9) at 73.910C. 
Decrease in intensity and shifting of the sharp melting peak 
of a drug in Nanocomposites indicates that the degree of 
crystallinity is considerably reduced.  
  
 
Fig.3 DSC of Fenofibrate                                         Fig.4 DSC of Nanocomposites 
                  
X-ray Diffraction Studies (XRD) 
X-ray diffraction was performed to determine the physical 
state of the drugs and its Nanocomposite. XRD patterns of 
drug and drug with polymer was demonstrated in Figures 5 
and 6. The pure drug shows sharp distinct characteristics 
peaks at 2θ diffraction angles for Fenofibrate at 14.27°, 
16.08°, 16.52°, 19.08°, 20.08° and 21.50° with an intense 
peak at 22.05° indicating crystalline nature of the drug. X-ray 
diffraction pattern Nanocomposite showed the absence of 
these distinct peaks; it was indicating that the crystalline 
nature of drug was reduced. 
 
 
Fig. 5 XRD of Fenofibrate                                 Fig.6 XRD of Nanocomposites 
 
Scanning Electron Microscopy (SEM) 
The SEM studies are generally done to study the morphology 
of the drug particles. The morphological characteristics of 
Nanocomposites are shown in the following Fig 7. 
 
Fig. 7 SEM of Nanocomposites 
 
Transmission Electron Microscopy: 
The TEM image of Nanocomposites is shown in Fig 8. TEM 
was taken to check the dispersion of drug nanocrystal in 
PVP. A TEM micrograph of Nanocomposites at 400 nm. Much 
lone Fenofibrate seen dispersed in the matrix indicating an 
absence of any aggregation. 
 
Fig.8 Tem of nanocomposites 
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Evaluation of Immediate-Release Tablets 
Pre-compression evaluation 
All the formulation mixtures were subjected to 
measurement of the angle of repose, Carr’s index and 
Hausner’s ratio. The results are shown in Table 7. From the 
angle of repose, Carr’s index and Hausner’s ratio data, it can 
be clearly concluded that FNOPVP and its mixture with 
different formulation components have excellent flow 
properties and fair to- good compressibility, which allows 
these formulation mixtures to be directly compressed into 
tablets and good flow of the mixture from the hopper with 
good content uniformity in the final tablets. 
 
Table 7: Evaluation of powder Blends 
Batch No. Compressibility index 
(%) 
Hausner’s ratio Angle of repose(θ) 
F1 12 ± 0.109 1.15 ± 0.06 29.82 ± 0.020 
F2 11 ± 0.106 1.17 ± 0.06 30.15 ± 0.19 
F3 13 ± 0.12 1.12 ± 0.03 28.76 ± 0.25 
F4 11 ± 0.18 1.18 ± 0.02 27.68 ± 0.65 
F5 10 ± 1.26 1.11 ± 0.1 25.68 ± 0.45 
 
Post-compression evaluation 
Prepared formulations were subjected to various 
compendial tests for post-compression evaluations such as 
hardness, friability, content uniformity of prepared tablets, 
DT. The results are shown in Table 8. All the parameters 
were within the limits given in the USP 30 (2007). 
 
Table 8: Evaluation of Tablets Characteristic 
Batch 
No. 
Thickness 
(mm) 
 
Hardness 
(kg/cm2) 
Friability 
(%) 
Weight 
variation (mg) 
Drug content 
uniformity (%) 
Disintegration 
time 
F1 4.42 ± 0.03 
 
4 ± 0.02 0.40 ± 0.045 498.75 ± 0.076 96.83% 
 
1 min 32 sec 
F2 4.42 ± 0.02 
 
4.1 ± 0.03 0.61 ± 0.040 496.62 ± 0.36 96.34% 
 
1min 
F3 4.43 ± 0.05 
 
4.3 ± 0.074 1.40 ± 0.023 497 ± 0.47 96% 
 
54 sec 
F4 4.41 ± 0.03 
 
4.5 ± 0.09 1.02 ± 0.023 497.98 ± 0.047 96.90% 
 
45 sec 
F5 4.52 ± 0.02 
 
4 ± 0.06 0.16 ± 0.046 498.8 ± 0.002 97% 
 
37 sec 
 
In-vitro drug release 
The optimized formulation (F5), based on disintegration 
studies, was subjected to an in-vitro drug-release study. 
After 30 min, formulation F4 showed 97.86±0.09% drug 
release.  
 
Fig. 9 In-vitro drug release graph 
Drug dissolution kinetics 
Various kinetic parameters studied for Fenofibrate 
Nanoocmposite formulation are illustrated in Table 9. The 
Nanocomposite formation process led to greater drug 
dissolution rates compared with the rate for the drug alone; 
around 50% of the loaded drug dissolved within the first 5 
min for Fenofibrate Nanocomposites. From the R2 value, it 
was concluded that the drug release profile of Fenofibrate 
(Nanocomposites) immediate-release tablet followed the 
First order release pattern. 
Table 9. Expected parameter and drug-release kinetic 
models 
Kinetics 
models 
Parameters Formulation 
(IR Tablet) 
Zero order R2 0.9052 
First order R2 0.9836 
Higuchi R2 0.8989 
Korsemayer-
peppas 
R2 0.9836 
 
Stability study 
The optimized formulation was subjected to stability studies 
according to ICH guidelines. Various variables, such as drug 
content, disintegration time and in-vitro drug release, were 
measured before and after 30, 60 and 90 days of storage. The 
results of stability studies are shown in Table 10. There was 
no significant change in the variables mentioned above 
following the elevated temperature and humidity conditions 
imposed during the stability study. Thus, it can be concluded 
that the prepared formulation is stable and not much 
affected by elevated humidity and temperature. 
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Table 10: Stability data of optimized formulation 
 
 
 
 
 
CONCLUSION 
The above studies successfully demonstrated the use of PVP 
as a carrier for the formulation of Nanocomposites by 
microwave-assisted techniques in solubility and dissolution 
enhancement. Solubility and dissolution studies confirm the 
use of these materials for solubility enhancement. The 
FNOPVP1:9 shows best results in solubility and dissolution 
enhancement. From the FTIR, DSC, XRD, SEM and TEM 
characterization it can be concluded that the drug has been 
converted into Nanocompposities and responsible for 
solubility enhancement. Characterization also confirms that 
there was no interaction in drugs and polymer. In-vitro 
assessment of optimized formulations has further confirmed 
the use of Nanocomposites for enhancing solubility and 
dissolution by the use of PVP. The stability studies state that 
Nanocomposites containing formulations are stable. Finally, 
from overall studies, we can conclude that Nanocomposites 
prepared by microwave technique can be successfully used 
for solubility, dissolution and bioavailability enhancement.   
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Sr. No. Parameter Months 
0 1 2 3 
1 Disintegration time (sec) 37 39 41 48 
2 % Drug release 97.86 97.12 97.1 96.98 
3 Drug Content (%) 97 96.98 96.97 96.95 
